Cholangiocarcinoma: Risk factors and clinical presentation

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 4, 2010, Pages 363-367

  Gatto, M ^a   Alvaro, Domenico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Cholangiocarcinoma; Cholangiocytes; Growth factors; Proliferation

Indexed keywords

BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURGERY; CAROLI DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FASCIOLA HEPATICA; HELMINTHIASIS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; STONE FORMATION; ULCERATIVE COLITIS; VATER PAPILLA TUMOR;

BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; HUMANS; RISK FACTORS;

EID: 77953152320     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. WELZEL TM, MCGLYNN KA, HSING AW, O'BRIEN TR, PFEIFFER RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-875.
2. FARLEY DR, WEAVER AL, NAGORNEY DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995; 70: 425-429.
3. KHAN SA, THOMAS HC, DAVIDSON BR, TAYLOR-ROBINSON SD. Cholangiocarcinoma. Lancet 2005; 366(9493): 1303-1314.
4. BLECHACZ B, GORES GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308-321.
5. Il Colangiocarcinoma. COMMISSIONE AISF 2009; WEBAISF.COM
6. ALVARO D, MANCINO MG, GLASER S, GAUDIO E, MARZIONI M, FRANCIS H, ALPINI G. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007; 132: 415-431.
7. FAVA G, MARZIONI M, BENEDETTI A GLASER S, DEMORROW S, FRANCIS H, ALPINI G. Molecular pathology of biliary tract cancers. Cancer Lett 2007; 250: 155-167.
8. BLECHACZ BR, GORES GJ. Cholangiocarcinoma. Clin Liver Dis 2008; 12: 131-150, ix.
9. OLNES MJ, ERLICH R. A review and update on cholangiocarcinoma. Oncology 2004; 66: 167-179.
10. LIM JH, PARK CK. Pathology of cholangiocarcinoma. Abdom Imaging 2004; 29: 540-547.
11. YACHIMSKI P, PRATT DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008; 42: 178-190.
12. BURAK K, ANGULO R PASHA TM, EGAN K, PETZ J, LINDOR KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-526.
13. ANGULO P, LINDOR KD. Primary sclerosing cholangitis. Hepatology 1999; 30: 325-332.
14. BOBERG KM, BERGQUIST A, MITCHELL S, PARES A ROSINA F, BROOMÉ U, CHAPMAN R, FAUSA O, EGELAND T, ROCCA G, SCHRUMPF E. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 1205-1211.
15. BERGQUIST A, EKBOM A, OLSSON R, KORNFELDT D, LÖÖF L, DANIELSSON A HULTCRANTZ R, LINDGREN S, PRYTZ H, SANDBERG-GERTZÉN H, ALMER S, GRANATH F, BROOMÉ U. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327. (Pubitemid 34194790)
16. CHARATCHAROENWITTHAYA P, ENDERS FB, HALLING KC, LINDOR KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48: 1106-1117.
17. SHIN HR, LEE CU, PARK HJ, SEOL SY, CHUNG JM, CHOI HC, AHN YO, SHIGEMASTU T. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996; 25: 933-940.
18. ANDOH H, YASUI O, KUROKAWA T, SATO T. Cholangiocarcinoma coincident with schistosomiasis japonica. J Gastroenterol 2004; 39: 64-68.
19. HONJO S, SRIVATANAKUL P, SRIPLUNG H, KIKUKAWA H, HANAI S, UCHIDA K, TODOROKI T, JEDPIYAWONGSE , KITTIWATANACHOT P, SRIPA B, DEERASAMEE S, MIWA M. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, north-east Thailand. Int J Cancer 2005; 117: 854-860. (Pubitemid 41599908)
20. SHAIB YH, EL-SERAG HB, DAVILA JA, MORGAN R, MCGLYNN KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626.
21. ROTA AN, WEINDUNG HK, GOODMAN PG. Cholangiocarcinoma associated with thorium dioxide (thorotrast): report of a case. Mich Med 1971; 70: 911-915.
22. ITO Y, KOJIRO M, NAKASHIMA T, MORI T. Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma. Cancer 1988; 62: 1153-1162.
23. ROBERTSON JF, RAINE PA. Choledochal cyst: a 33-year review. Br J Surg 1988; 75: 799-801.
24. DE VRIES JS, DE VRIES S, ARONSON DC, BOSMAN DK, RAUWS EA, BOSMA A HEU HA, GOUMA DJ, VAN GULIK TM. Choledochal cysts: age of presentation, symptoms, and late complications related to Todani's classification. J Pediatr Surg 2002; 37: 1568-1573.
25. PISANO G, DONLON JB, PLATELL C, HALL JC. Cholangiocarcinoma in a type III choledochal cyst. Aust N Z J Surg 1991; 61: 855-857.
26. VOYLES CR, SMADJA C, SHANDS WC, BLUMGART LH. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg 1983; 118: 986-988.
27. SU CH, SHYR YM, LUI WY P'ENG FK. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 1997; 84: 969-973.
28. ISHIGURO S, INOUE M, KURAHASHI N, IWASAKI M, SASAZUKI S, TSUGANE S. Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study); with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control 2008; 19: 33-41.
29. HSING AW, GAO YT, HAN TQ, RASHID A SAKODA LC, WANG BS, SHEN MC, ZHANG BH, NIWA S, CHEN J, FRAUMENI JF Jr. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2007; 97: 1577-1582. (Pubitemid 350175843)
30. ROUKOUNAKIS NE, KUHN JA, MCCARTY TM. Association of an abnormal pancreaticobiliary junction with biliary tract cancers. Proc (Bayl Univ Med Cent) 2000; 13: 11-13.
31. GWAK GY YOON JH, LEE SH, LEE SM, LEE HS, GORES GJ. Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes. J Cancer Res Clin Oncol 2006; 132: 771-779.
32. COSTAMAGNA G, TRINGALI A, SHAH SK, MUTIGNANI M, ZUCCALÀ G, PERRI V. Long-term follow-up of patients after endoscopic sphincterotomy for choledocholithiasis, and risk factors for recurrence. Endoscopy 2002; 34: 273-279. (Pubitemid 34279514)
33. STRÖMBERG C, LUO J, ENOCHSSON L, ARNELO U, NILSSON M. Endoscopic sphincterotomy and risk of malignancy in the bile ducts, liver, and pancreas. Clin Gastroenterol Hepatol 2008; 6: 1049-1053.
34. MORTENSEN FV, JEPSEN R TARONE RE, FUNCH-JENSEN P, JENSEN LS, SØRENSEN HT. Endoscopic sphincterotomy and long-term risk of cholangiocarcinoma: a population-based follow-up study. J Natl Cancer Inst 2008; 100: 745-750.
35. DONATO F, GELATTI U, TAGGER A, FAVRET M, RIBERO ML, CALLEA F, MARTELLI C, SAVIO A, TREVISI P, NARDI G. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12: 959-964.
36. YAMAMOTO S, KUBO S, HAI S, UENISHI T, YAMAMOTO T, SHUTO T, TAKEMURA S, TANAKA H, YAMAZAKI O, HIROHASHI K, TANAKA T. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 95: 592-595. (Pubitemid 39089641)
37. LU H, YE MQ, THUNG SN, DASH S, GERBER MA. Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients. Chin Med J (Engl) 2000; 113: 1138-1141.
38. KOBAYASHI M, IKEDA K, SAITOH S, SUZUKI F, TSUBOTA A, SUZUKI Y, ARASE Y, MURASHIMA N, CHAYAMA K, KUMADA H. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000; 88: 2471-2477.
39. PERUMAL V, WANG J, THULUVATH P, CHOTI M, TORBENSON M. Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol 2006; 37: 1211-1216.
40. NATIONAL TOXICOLOGY PROGRAM. NTP Toxicology and carcinogenesis studies of a mixture of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) (CAS No. 1746-01-6), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (CAS No. 57117-31-4), and 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies). Natl Toxicol Program Tech Rep Ser 2006; (526): 1-180.
41. WELZEL TM, GRAUBARD BI, EL-SERAG HB, SHAIB YH, HSING AW, DAVILA JA, MCGLYNN KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228.
42. AHRENS W, TIMMER A VYBERG M, FLETCHER T, GUÉNEL P, MERLER E, MERLETTI F, MORALES M, OLSSON H, OLSEN J, HARDELL L, KAERLEV L, RAVERDY N, LYNGE E. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroenterol Hepatol 2007; 19: 623-630.
43. CHA JM, KIM MH, LEE SK, SEO DW, LEE SS, LEE JH, LEE SG, JANG SJ. Clinicopathological review of 61 patients with early bile duct cancer. Clin Oncol (R Coll Radiol) 2006; 18: 669-677.
44. ANDERSON CD, PINSON CW, BERLIN J, CHARI RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43-57.
45. FEVERY J, VERSLYPE C, LAI G, AERTS R, VAN STEENBERGEN W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 3123-3135.
46. ALEXOPOULOU A, SOULTATI A, DOURAKIS SP, VASILIEVA L, ARCHIMANDRITIS AJ. Cholangiocarcinoma: a 7-year experience at a single center in Greece. World J Gastroenterol 2008; 14: 6213-6217.
47. HANN LE, GETRAJDMAN GI, BROWN KT, BACH AM, TEITCHER JB, FONG Y, BLUMGART LH. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. AJR Am J Roentgenol 1996; 167: 1017-1021.
48. MORRIS-STIFF G, BHATI C, OLLIFF S, HÜBSCHER S, GUNSON B, MAYER D, MIRZA D, BUCKELS J, BRAMHALL SR. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg 2008; 25: 126-132.
49. BJÖRNSSON E, ANGULO P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007; 102: 1677-1682.